GLP-1 Scale-Up: Turning Breakthrough Demand into Reliable Enterprise Performance
GLP-1 therapies have become one of the most important growth stories in global pharmaceuticals. They are reshaping obesity and diabetes care, attracting payer and policy attention, changing patient expectations, and forcing companies to rethink the speed and scale at which manufacturing, access, and commercial operations must operate.
Morgan Stanley projected in April 2026 that the global GLP-1 market could reach $190 billion by 2035, more than double 2025 levels. That growth potential is not just a demand story. It is an enterprise-capacity story. The companies competing in this market must scale production, manage supply constraints, support patient access, navigate reimbursement, prepare for oral formulations, and expand globally without allowing demand volatility to overwhelm the operating model.
The pressure is already visible in capital deployment. Reuters reported that Eli Lilly plans a $6 billion manufacturing facility in Huntsville, Alabama tied in part to small-molecule and peptide medicines, including its oral GLP-1 candidate orforglipron, as part of a broader domestic manufacturing expansion. In a category where supply, access, and affordability will shape adoption, execution has become a strategic differentiator.
Breakthrough demand only creates enterprise value when the operating model can scale with it.
The Demand Curve Is Moving Faster Than Traditional Pharma Infrastructure
The GLP-1 market is expanding across multiple dimensions at once: indication growth, international adoption, new formulations, patient segments, pharmacy channels, employer and payer decisions, and physician demand. That makes traditional linear launch models less effective. Demand can surge faster than capacity, coverage, training, patient onboarding, and distribution systems are prepared to handle.
For CEOs, the risk is not simply unmet demand. It is unmanaged demand. When supply is constrained, patients switch, physicians lose confidence, payers tighten rules, and competitors can gain share. When supply expands faster than access workflows, patient-support models, or channel capacity, the organization can create inventory imbalances, service failures, and margin leakage.
GLP-1 scale-up therefore requires more than manufacturing investment. It requires integrated control across demand forecasting, supply planning, market access, patient services, distribution, quality, medical education, and field execution.
Manufacturing Scale-Up Must Protect Quality, Reliability, and Flexibility
GLP-1 manufacturing is not a simple capacity exercise. Peptides, injectables, pens, fill-finish capacity, device components, cold chain, packaging, and future oral formulations each introduce different constraints. Scaling quickly while preserving quality requires strong technology transfer, validation discipline, supplier readiness, maintenance reliability, deviation control, and batch-release performance.
The stakes are high because the market is both fast-growing and visible. Supply interruptions in a breakthrough category can become reputational, regulatory, and commercial events. Building plants and adding lines are necessary, but capacity does not become enterprise value until it is qualified, staffed, supplied, validated, released, and connected to demand.
The companies that win will manage manufacturing expansion as a cross-functional performance system. Capital projects, quality, procurement, workforce capability, production scheduling, commercial forecasts, and regulatory commitments must move together.
Global Expansion Adds Variability to the Operating Model
The GLP-1 opportunity is not confined to a single country, payer environment, or channel model. Morgan Stanley highlighted international markets, including Brazil and China, as potential areas of rapid expansion as affordability improves and broader patient populations become reachable. That creates a new layer of variability in regulatory timing, pricing, access, patient education, distribution, and supply allocation.
A global GLP-1 growth model must therefore balance enterprise scale with local market requirements. The company must determine where supply should be allocated, which markets can be served profitably, which patient segments require additional support, and where local access dynamics could either accelerate or slow adoption. These decisions cannot be made function by function.
The companies that execute best will have an operating model that can adjust quickly as the demand curve changes. They will be able to shift supply priorities, revise forecasts, deploy commercial resources, and manage access workflows without creating confusion across regions or channels.
The Category Is Moving from Scarcity to Control
Early GLP-1 growth was defined partly by scarcity. The next phase will be defined by control. As capacity expands and competitors introduce new formulations, manufacturers will need to compete on reliability, patient experience, access, evidence, and cost-to-serve. That requires a more mature enterprise operating cadence than the emergency routines that often accompany supply-constrained growth.
Control also means knowing the cost of complexity. New devices, dose forms, indications, packaging formats, payer rules, and patient-support models can all increase market reach, but they can also create operational strain. Leaders need a clear view of which sources of complexity increase value and which simply consume capacity, working capital, and management attention.
Patient Access and Commercial Control Will Shape the Market
The next phase of GLP-1 growth will be shaped by access as much as by demand. Payers, employers, Medicare policy, international pricing, generics in some markets, and patient affordability will influence adoption. Companies will need to manage coverage requirements, prior authorization, adherence support, physician education, pharmacy fulfillment, and patient expectations with much more precision.
Oral therapies could broaden the market further, but they may also change manufacturing, pricing, distribution, and adherence dynamics. International expansion can create large new demand pools, but it also introduces local market access, supply, regulatory, and affordability challenges. The operating model must be flexible enough to respond to these different growth patterns without creating fragmentation.
In this environment, commercial execution cannot be separated from supply execution. Forecasts, access decisions, channel allocation, and patient-support capacity must be synchronized so demand generation does not outpace the organization’s ability to serve patients reliably.
The Brooks International Perspective
From Brooks International’s perspective, the GLP-1 opportunity is a scale-up challenge across the enterprise. The category’s growth potential is clear, but capturing that potential requires disciplined execution across manufacturing, supply chain, quality, market access, commercial operations, and patient support.
Brooks International would view the highest-value opportunities in the operating system that links these functions. Can the company see the true constraints in production, fill-finish, device supply, cold chain, reimbursement, patient onboarding, and distribution? Can leadership remove bottlenecks quickly? Can commercial commitments be matched to supply reality? Can capital projects move from announcement to qualified output without drift?
The most effective organizations will build a management cadence that treats GLP-1 scale-up as one integrated performance agenda. That includes weekly and monthly control points, aligned leading indicators, clear escalation paths, and cross-functional accountability for turning demand into shipped product, patient starts, adherence, revenue, and cash flow.
This also requires strong control of working capital and customer commitments. As GLP-1 demand expands, inventory decisions, safety-stock positions, channel allocations, returns exposure, and service expectations must be managed against the same operating facts. A company can have strong demand and still lose value if it overcommits supply, underestimates channel complexity, or allows fragmented regional decisions to create avoidable cost and patient-access disruption. Leaders also need to understand how each operational decision affects the patient experience, because missed fills, inconsistent access, or confusing support pathways can weaken adherence and reduce the long-term value of the category.
The GLP-1 market rewards speed, but speed without control can create waste, service failures, and missed value. Brooks International’s perspective is that breakthrough demand must be matched with an operating model capable of reliable, repeatable, and financially disciplined scale.
What Pharmaceutical Leaders Should Be Asking Now
The leadership agenda should focus on whether the enterprise can scale demand, supply, and access together:
- Where are the true constraints: API, peptide synthesis, fill-finish, device supply, packaging, cold chain, quality release, or patient access?
- Are commercial forecasts directly connected to manufacturing and supply plans, or are they being managed in separate cycles?
- Can capital projects move from investment approval to qualified capacity with the speed and discipline the market requires?
- Are patient-support and reimbursement workflows ready for the next wave of demand?
- How will oral formulations, international expansion, and payer policies change the operating model?
- Does leadership have the leading indicators needed to intervene before supply or access issues become revenue loss?
These questions matter because GLP-1 growth will not be captured by demand alone. It will be captured by the organizations that can make scale-up visible, controlled, and accountable.
The Leadership Imperative
The GLP-1 category has already changed expectations for pharmaceutical growth. It is now changing expectations for manufacturing readiness, access execution, patient support, and enterprise coordination.
For billion-dollar pharmaceutical companies, the mandate is to move beyond breakthrough science and build the operating capability required to serve a market of unprecedented scale. The winners will be those that turn demand into reliable supply, reliable supply into patient access, and patient access into durable enterprise performance.
In the GLP-1 market, scale is no longer just a manufacturing objective. It is a full-enterprise execution requirement.
